Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial St...Read More
Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other 510...Read More
. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 Internatio...Read More